← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #42 OF 1,000 MOST-CITED

Case history records- inadequate or inadequate

FDA cited this observation 456 times across 446 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Bioresearch Monitoring456
BY FISCAL YEAR
FY202617
FY202547
FY202455
FY202349
FY202236
FY202148
FY202030
FY201961
FY201869
FY201744

How FDA worded it — real examples

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Apinya B. Vutikullird, D.O. · Long Beach, California · Bioresearch Monitoring · 2026-05-12

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Diana T. Widicus, M.D. · Springfield, Illinois · Bioresearch Monitoring · 2026-04-03

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Jeffrey R. Hoodin, M.D. · Phoenix, Arizona · Bioresearch Monitoring · 2026-03-13

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Javier Martin-Broto, MD · Madrid · Bioresearch Monitoring · 2026-02-26

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Dr. Minoru Kato · Osaka · Bioresearch Monitoring · 2026-01-29

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Prof. Bernardo Leon Rapoport · Johannesburg · Bioresearch Monitoring · 2026-01-29

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

GCP discipline

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →